Scilex Holding (SCLXW) Non-Current Deffered Revenue (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Non-Current Deffered Revenue of $1.9 million in Q1 2026, down 4.7% quarter-over-quarter from $2.0 million in Q4 2025, and down 16.99% on a YoY basis from $2.3 million in Q1 2025.
Scilex Holding (SCLXW) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Scilex Holding's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 16.99% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 16.99% YoY), while the FY2025 annual figure was $2.0 million, down 16.63% from the prior year.
- Non-Current Deffered Revenue was $1.9 million for Q1 2026 at Scilex Holding, down from $2.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.2 million in Q1 2022 to a low of $1.9 million in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $3.1 million across 5 years, with a median of $2.8 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue changed 0.0% in 2022, then tumbled 41.93% in 2023.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $3.4 million in 2022, then declined by 14.53% to $2.9 million in 2023, then retreated by 15.44% to $2.4 million in 2024, then declined by 16.63% to $2.0 million in 2025, then fell by 4.7% to $1.9 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $1.9 million (Q1 2026), $2.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Scilex Holding | - | - | 4.15 Mn | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.95 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 2.67 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | 3.01 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 3.26 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Jun 30, 2022 | 5.19 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Sep 30, 2021 | 5.19 Mn |
| Jun 30, 2021 | 5.19 Mn |
| Mar 31, 2021 | 5.19 Mn |